Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study

[1]  Xiao Qin,et al.  Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt , 2021, Abdominal Radiology.

[2]  E. Verna,et al.  Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era—An ALTA Group Study , 2021, The American journal of gastroenterology.

[3]  S. Raman,et al.  Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  Hongyu Wang,et al.  Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS , 2021, European Radiology.

[5]  J. Trebicka,et al.  Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. , 2021, Journal of hepatology.

[6]  M. García-Fiñana,et al.  Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach , 2019, Hepatology.

[7]  Non-communicable Disease Control.  [Strategies of primary prevention of liver cancer in China: Expert Consensus (2018)]. , 2019, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[8]  V. Wong,et al.  Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. , 2018, Journal of hepatology.

[9]  Xu Zhou,et al.  Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study , 2018, Oncology letters.

[10]  Kai Li,et al.  Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus , 2017, CardioVascular and Interventional Radiology.

[11]  R. Lencioni,et al.  Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data , 2016, Hepatology.

[12]  R. Golfieri,et al.  Refining prognosis after trans‐arterial chemo‐embolization for hepatocellular carcinoma , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[13]  S. Ahn,et al.  Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial‐embolization prognostic score , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[14]  S. Ahn,et al.  Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapy , 2015, Hepatology.

[15]  S. Kwan,et al.  Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts , 2015, CardioVascular and Interventional Radiology.

[16]  K. Moons,et al.  Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement , 2015, BJOG : an international journal of obstetrics and gynaecology.

[17]  G. Collins,et al.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement , 2015, BMC Medicine.

[18]  J. Minocha,et al.  Characterization of liver function parameter alterations after transjugular intrahepatic portosystemic shunt creation and association with early mortality. , 2014, AJR. American journal of roentgenology.

[19]  Xuefeng Luo,et al.  Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. , 2014, Diagnostic and interventional radiology.

[20]  D. Fan,et al.  Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[21]  H. Shan,et al.  Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. , 2014, Radiology.

[22]  D. Bettinger,et al.  Influence of the transjugular intrahepatic portosystemic stent on firstline treatment of hepatocellular carcinoma , 2013, Hepatology.

[23]  D. Fan,et al.  Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review , 2013, Asia-Pacific journal of clinical oncology.

[24]  D. Naeger,et al.  Efficacy of TACE in TIPS Patients: Comparison of Treatment Response to Chemoembolization for Hepatocellular Carcinoma in Patients With and Without a Transjugular Intrahepatic Portosystemic Shunt , 2013, CardioVascular and Interventional Radiology.

[25]  A. Burroughs,et al.  A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  A. Santoro,et al.  Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. , 2012, Journal of hepatology.

[27]  T. Vogl,et al.  Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations , 2011, CardioVascular and Interventional Radiology.

[28]  S. Chang,et al.  Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis , 2009, European journal of gastroenterology & hepatology.

[29]  T. Mok,et al.  New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Kim,et al.  The model for end‐stage liver disease (MELD) , 2007, Hepatology.

[31]  E. Cholongitas,et al.  Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.

[32]  C. Flechtenmacher,et al.  Percutaneous Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts , 2006, CardioVascular and Interventional Radiology.

[33]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[34]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[35]  F. Chan,et al.  Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus–infected patients , 2000, American Journal of Gastroenterology.

[36]  M. D. Patel,et al.  Transjugular intrahepatic portosystemic shunts: accuracy of Doppler US in determination of patency and detection of stenoses. , 1996, Radiology.

[37]  M. Kudo,et al.  The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. , 2017, Journal of hepatology.

[38]  D. Naeger,et al.  Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? , 2013, Journal of vascular and interventional radiology : JVIR.

[39]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.